Similar Papers

Paper Title
Journal
Date
Author
Effect of SMARCA4 mutations on the outcomes of patients with advanced EGFR mutant lung adenocarcinoma
X Liang ... R H Guo
Zhonghua yi xue za zhi | VOL. 105
X Liang, et. al.X Liang ... R H Guo
28 Jan 2025
Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation.
Po-Yen Chen ... Chien-Ning Hsu
Frontiers in Pharmacology | VOL. 12
Po-Yen Chen, et. al.Po-Yen Chen ... Chien-Ning Hsu
09 Aug 2021
Effect of thoracic radiotherapy dose on the prognosis of advanced lung adenocarcinoma harboring EGFR mutations
Hongyue Qin ... Jiaojiao Ke
BMC Cancer | VOL. 22
Hongyue Qin, et. al.Hongyue Qin ... Jiaojiao Ke
24 Sep 2022
Abstract A109: AZD9291: an irreversible, potent and selective third generation tyrosine kinase inhibitor (TKI) targeting EGFR activating (EGFRm+) and resistance (T790M) mutations in advanced lung adenocarcinoma.
...
Molecular Cancer Therapeutics | VOL. 12
, et. al. ...
01 Nov 2013
View more papers

More From: Annals of Oncology

Paper Title
Journal
Date
Author
Expanding the role of CDK4/6 inhibitors in early breast cancer: insights from the NATALEE trial
Marcela Carausu ... Michail Ignatiadis
Annals of Oncology | VOL. 36
Marcela Carausu, et. al.Marcela Carausu ... Michail Ignatiadis
01 Feb 2025
Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors
J.M Riedl ... R.B Corcoran
Annals of Oncology | VOL. -
J.M Riedl, et. al.J.M Riedl ... R.B Corcoran
01 Feb 2025
Whole genome sequencing powered ctDNA sequencing for breast cancer detection
I Garcia-Murillas ... N.C Turner
Annals of Oncology | VOL. -
I Garcia-Murillas, et. al.I Garcia-Murillas ... N.C Turner
01 Feb 2025
Table of Contents
-
Annals of Oncology | VOL. 36
--
01 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.